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Subcutaneous and sublingual levodopa
methyl ester in Parkinson's disease
Subcutaneous continuous infusions or inter-
mittent injections of the dopamine receptor
agonist apomorphine have proved to be an
effective treatment for motor fluctuations in
patients with Parkinson's disease receiving
long term levodopa treatment.'2 Levodopa
itself is impractical for chronic parenteral
treatment because of its low solubility and
high acidity. The highly soluble levodopa
methyl ester (LDME), however, might be a
more suitable candidate for parenteral
application3 and its longer half-life compared
with that of apomorphine could be of clinical
advantage. We have therefore investigated
the possibility of administering LDME both
by the subcutaneous and, following a
previous anecdotal report,4 by the sublingual
route.
Five sublingual and five subcutaneous
doses ofLDME were given to seven patients
with idiopathic Parkinson's disease and
motor fluctuations. Their mean age was 59
years, mean duration of disease 12 (4-22)
years, mean duration of levodopa therapy 9 5
(1 5-19) years and mean stage of Hoehn and
Yahr 3-4 when "off" and 2-4 when "on". All
patients were known to respond to their first
morning dose of 100 or 200 mg of oral
levodopa plus decarboxylase inhibitor within
15 to 30 minutes and the mean duration of
effect was 135 (90-120) minutes. On test days
the morning dose was replaced by 1 ml of
LDME (equivalent to 200 mg levodopa)
either injected subcutaneously or given
sublingually. Patients were given 50 mg of
oral benserazide one hour before the LDME
challenge. Subcutaneous doses were injected
in two boluses of 0 5 ml each into different
sites of the abdominal wall. With sublingual
applications patients were instructed to keep
the liquid underneath their tongue as long as
possible and spit it out as soon as they felt
forced to swallow. Motor assessments were
carried out using the modified Webster scale
at baseline and at the time of maximum
therapeutic effect as well as unilateral hand
tapping tests 10 minutes before and every 10
minutes after administration ofLDME until
drug effects had completely worn off or up to
one and a half hours when there was no
clinical effect.
Two patients switched "on" with sub-
cutaneous LDME with the same quality and
duration of therapeutic effect seen after their
oral levodopa doses. The time from injection
to full switch "on" was 60 minutes in both
patients. Two patients had no effect over the
entire observation period of 90 minutes and
another one experienced onset-of-dose dys-
kinesias continuing for 110 minutes without
ever switching fully "on". One ofthe respon-
ders then received a second injection which
after a latency of 80 minutes produced some
clinical effects with an inferior "on"-quality
lasting for only 15 minutes. All patients had
burning sensations at the injection site with
rapidly developing nodules which slowly
disappeared over two to four days.
Sublingual LDME was ineffective in all
patients who managed to keep the liquid
underneath their tongues for an average of 13
(5-20) minutes. No local side effects were
observed.
The cause for the unpredictable response
to subcutaneous LDME is unclear. The rate
of de-esterification of LDME and resulting
absorption of levodopa is influenced by pH,
temperature and distribution and activity of
esterases.' Different individual conditions at
the subcutaneous injection site may therefore
be responsible for the varying clinical effects
observed. As the local toxic reaction to sub-
cutaneous LDME was seen in both respon-
ders and non-responders it is unlikely to be a
Cortical nicotinic receptors in
Alzheimer's disease and Parkinson's
disease
Cognitive impairment and central cholinergic
dysfunction are common features of
Alzheimer's disease (AD) and Parkinson's
disease (PD). Degeneration of subcortico-
cortical cholinergic systems and reductions in
cortical pre-synaptic cholinergic markers,
such as choline acetyltransferase (CAT)
activity, have been consistently demonstrated
in AD and PD.' 2 Most investigations of
muscarinic cholinergic receptors in the
neocortex indicate that receptor binding is
unchanged inAD and increased in PD.34 The
status ofnicotinic cholinergic receptors is less
clear. We have examined nicotinic receptor
binding and CAT activity in the cortex inAD
and PD.
Brain tissue was obtained at necropsy from
ten patients with AD and from ten matched
control subjects with no evidence of
major reason for poor absorption.
The failure of sublingual LDME to
produce clinical effects provides no evidence
for absorption through the oral mucosa.
Although the number of patients in this
trial was small we conclude that due to the
variability and unreliability of clinical res-
ponse subcutaneous LDME is unlikely to
become a practical treatment for fluctuating
Parkinson's disease.
We gratefully acknowledge Chiesi Farmaceutical,
Parma, Italy for providing levodopa methyl ester
solution.
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neurological or psychiatric diseases, and from
ten patients with PD, five of whom were
clinically demented according to DSM III
criteria, and ten matched controls. AD and
PD were confirmed neuropathologically. The
Parkinsonian patients had been treated with
levodopa up to the time of death. Patients
with AD and controls had not received any
medication that is known to affect the central
nervous system. Using washed membrane
homogenates we performed saturation
analysis for nicotinic receptors with (-)-[3H]-
nicotine (concentrations 05-64 nM) in the
frontal cortex (Brodmann area 8) and
temporal cortex (Brodmann area 38). Non-
specific binding was defined by unlabelled
nicotine. Protein concentrations and enzyme
activities were measured by standard
techniques.
CAT activity was reduced in the frontal
and temporal cortex of patients with AD and
demented and non-demented patients with
PD (table). Cortical maximal densities of
Table Mean (SEM) maximal nicotinic receptor binding in the cortex
Control AD Control PD(n= 10) (n= 10) (n= 10) (n= 10)
Age (year) 79-8 (2-4) 82.7 (2-3) 73 1(5-5) 73-7 (2 5)
Death to brain
removal (h) 40 5 (6-0) 42-6 (6-2) 19-6 (2 4) 18-1 (2-7)
CAT activity
in frontal cortex 4-0 (0 7) 1-8 (0 4)* 4-2 (0-4) 2-3 (0-4)*in temporal cortex 4-4 (0-3) 1-4 (0 3)* 4-5 (0-2) 2 5 (0-3)*(-)-['H]-nicotine binding
infrontal cortex 21 7 (1-3) 11-0(1-4)* 23-1 (1-1) 12 2 (13)*in temporal cortex 26-9 (1-1) 11 5 (1-2)* 25-0 (1-1) 13-3 (0 9)*
Wilcoxon's rank-sum text: *p < 0 05.
CAT activity in nmol/h/mg protein; nicotine binding as B.,,, in fmol/mg protein.
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nicotinic receptors ' were substantially
reduced in both AD and PD. There were no
changes of the equilibrium dissociation
constants (KD).
The exact cellular location of nicotinic
cholinergic receptors in the cerebral cortex is
not known. The parallel changes in these
receptors and CAT activity in AD and PD
suggest that they are located pre-synaptically
on degenerating cholinergic axons. This view
is consistent with the finding that nicotine
stimulates the release of acetylcholine from
cholinergic terminals in the cortex.5 The
present results point to the potential for
stimulation of the remaining nicotinic
receptors as a treatment of the cholinergic
deficit in AD and PD and provide a rationale
for a therapeutic trial of selective nicotinic
agonists.
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Industrial exposure to cobalt causing
optic atrophy and nerve deafness: a case
report
A 48 year old man presented with a seven
month history of progressive bilateral deaf-
ness with tinnitus and occasional vertigo and
a six month history of visual failure. He had
been exposed to raw cobalt powder for 20
months, working 50 hours a week. He stop-
ped work in November 1988. In spite of face
masks, some of the powder was inhaled. He
smoked ten cigarettes a day and drank two
pints of lager a week. There was no drug
exposure or family history of note. On
examination his visual acuity was 6/36 in the
right eye and 6/60 in the left eye. The
temporal margins of the discs were pale.
Hearing was impaired bilaterally. Full
haematological investigation, chest radio-
graph and CT brain scan were normal. CSF
showed a raised protein of 70 mgs/100 ml
with oligoclonal IgG banding. Syphilis
serology was negative. Blood cobalt was
234 jgm/1 (normal <2) in February 1989,
falling to 14 7 ygm/l by May 1989. Twenty
four hour urinary cobalt was 119 pgm/24 hr
(normal <51) in February 1989. VERs in
February 1989 were right eye 125 ms, left eye
126 5 ms, in May 1989, 118 ms on both sides,
and in February 1990, 109 ms on both sides.
By January 1990 the visual acuity improved
to 6/12 bilaterally.
Audiometry improved from December
1988 to February 1990 as shown. The patient
felt his hearing was back to normal by the end
of 1989.
Cobalt is a relatively rare metal. Today
most of it is produced as a by-product of
copper or silver production. Cobalt is widely
used in the making ofhard metals in industry,
for example, drill tips and gas turbine blades.
It is also used in medicine. The metal alloy,
vitallium, is a strong and corrosion resistant
metal used for prostheses in replacement
bone surgery, for example, hip and knee
joints.'
Cobalt has also been used clinically in the
treatment of certain types of anaemia; when
given to normal and anaemic patients it has
produced a reticulocytosis. Medically, it has
been used as an antidote for certain types of
poisoning, such as cyanide, and as a poten-
tiator of the action of antibiotics or hydrocor-
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tisone. Radium has virtually been replaced by
Cobalt 60 for radiotherapy.'
Many adverse reactions have been reported
following its clinical use, although there are
remarkably few reports of severe poisoning as
a result of industrial exposure. Reactions to
cobalt have included anorexia, nausea and
vomiting, diarrhoea, precordial pain,
cardiomyopathy, skin rashes, flushing, nerve
deafness, renal damage, hypothyroidism,
asthma and pulmonary fibrosis and possible
optic atrophy.'` Despite the long list of
adverse reactions, the complications that
developed in this case, optic atrophy and
nerve deafness, have never been reported to
occur together.
Licht, Oliver and Rachmilewitz4 described
the only previous case report of optic atrophy
possibly secondary to cobalt chloride. The
patient, a 32 year old Jewish man, was found
to have a pancytopenia with a hypercellular
bone marrow of unknown aetiology. The
anaemia responded to courses of cobalt
chloride given on four different occasions. On
two occasions the drug had to be discontinued
because of nausea and vomiting. On the
fourth occasion, after a fifteen week course of
cobalt chloride, the patient began to complain
ofdeteriorating vision. Ophthalmological fin-
dings and fluroscein angiography indicated
the presence of optic atrophy and abnormal
choroidal perfusion. Their patient had
received a total dose of 73 g of cobalt chlor'ide
over a period of three years. Following cessa-
tion of the drug there was no further
deterioration in vision despite the progres-
sion of the underlying disease, suggesting
that the optic atrophy may have been due to
cobalt toxicity.
Gardner' studied 17 patients with anaemia
and uraemia treated with cobalt chloride.
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Figure Audiograms showing improvement of hearing after withdrawalfrom cobalt exposure.
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